Schroder Investment Management Group Increases Stake in Amgen Inc.

Hedge fund raises position in major biotech company by 17% in Q3 2025.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Schroder Investment Management Group increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 17.0% during the third quarter of 2025, according to a recent SEC filing. The fund now owns 333,529 shares of the medical research company's stock, valued at approximately $91,377,000.

Why it matters

Amgen is a leading global biotechnology company focused on developing innovative human therapeutics. Institutional investors closely monitor changes in major shareholders as it can signal shifts in market sentiment and future strategic direction for the company.

The details

Schroder Investment Management Group added 48,384 shares of Amgen to its portfolio during the third quarter, bringing its total position to 333,529 shares. This represents approximately 0.06% ownership of the outstanding shares of the medical research company.

  • Schroder Investment Management Group increased its stake in Amgen during the third quarter of 2025.

The players

Schroder Investment Management Group

A global asset management firm that provides investment management products and services to institutional and retail clients worldwide.

Amgen Inc.

An American multinational biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics.

Got photos? Submit your photos here. ›

The takeaway

The increased stake by Schroder Investment Management Group in Amgen signals continued institutional investor confidence in the biotech company's long-term growth potential despite broader market volatility.